We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate [Yahoo! Finance]
Cadrenal Therapeutics, Inc. (CVKD)
Company Research
Source: Yahoo! Finance
But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. Given its strong share price performance, we think it's worthwhile for Cadrenal Therapeutics shareholders to consider whether its cash burn is concerning. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. View our latest analysis for Cadrenal Therapeutics A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. When Cadrenal Therapeutics last reported its June 2024 balance sheet in August 2024, it had zero debt and cash worth US$5.0m. Looking at the last year, the company burnt through US$4.7m. That means it had a cash runway of around 13 months as of June 2024. That
Show less
Read more
Impact Snapshot
Event Time:
CVKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVKD alerts
High impacting Cadrenal Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CVKD
News
- Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook [Yahoo! Finance]Yahoo! Finance
- Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech OutlookPR Newswire
- CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESSPR Newswire
- Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) had its price target raised by analysts at HC Wainwright from $3.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
- CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATEPR Newswire
CVKD
Sec Filings
- 11/14/24 - Form S-3
- 11/14/24 - Form SC
- 11/14/24 - Form D
- CVKD's page on the SEC website